{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:27:23Z","timestamp":1794670043893,"version":"4.9.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI169385"],"award-info":[{"award-number":["U01 AI169385"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["T32 AI007613"],"award-info":[{"award-number":["T32 AI007613"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["5KL2TR001865"],"award-info":[{"award-number":["5KL2TR001865"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI169385"],"award-info":[{"award-number":["U01 AI169385"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI169385"],"award-info":[{"award-number":["U01 AI169385"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI169385"],"award-info":[{"award-number":["U01 AI169385"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI169385"],"award-info":[{"award-number":["U01 AI169385"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI169385"],"award-info":[{"award-number":["U01 AI169385"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI169385"],"award-info":[{"award-number":["U01 AI169385"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI169385"],"award-info":[{"award-number":["U01 AI169385"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI169385"],"award-info":[{"award-number":["U01 AI169385"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI169385"],"award-info":[{"award-number":["U01 AI169385"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Broadly neutralizing antibodies (bnAbs) are promising agents for HIV-1 treatment and prevention. However, the genetic barriers and mutational pathways to viral resistance, which can limit therapeutic antibody utility, remain poorly defined. Here we developed a medium-to-high throughput approach to determine the mutations that confer resistance to neutralization by the bnAbs 3BNC117 and 10-1074 currently in clinical development. We performed 7,776 parallel selection experiments to identify bnAb resistance mutations in 15 primary isolates that span global HIV-1 genetic diversity. There was substantial variability among HIV-1 isolates in the identity of mutations that conferred bnAb resistance. For 12 of 15 HIV-1 isolates, single amino acid changes could increase bnAb IC\n                    <jats:sub>80<\/jats:sub>\n                    to &gt;10\u2009\u03bcg\u2009ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    . Some 3BNC117 resistance mutations conferred resistance to additional bnAbs targeting the same or different epitopes, and unconventional escape mechanisms were occasionally encountered. These data provide a rationale for selecting bnAb combinations that are most likely to achieve treatment success.\n                  <\/jats:p>","DOI":"10.1038\/s41564-026-02347-x","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:03:32Z","timestamp":1778490212000},"page":"1573-1584","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diverse paths to broadly neutralizing antibody escape among HIV-1 strains"],"prefix":"10.1038","volume":"11","author":[{"given":"Alex C.","family":"Stabell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2023-051X","authenticated-orcid":false,"given":"Songhee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1029-7253","authenticated-orcid":false,"given":"Debby J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy L.","family":"Lavine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian Mejia","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viren A.","family":"Baharani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Patejak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0592-8564","authenticated-orcid":false,"given":"Michel C.","family":"Nussenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1727-8693","authenticated-orcid":false,"given":"Marina","family":"Caskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2368-3719","authenticated-orcid":false,"given":"Paul D.","family":"Bieniasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7889-0766","authenticated-orcid":false,"given":"Theodora","family":"Hatziioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2347_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/00002030-199002000-00002","volume":"4","author":"J Albert","year":"1990","unstructured":"Albert, J. et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4, 107\u2013112 (1990).","journal-title":"AIDS"},{"key":"2347_CR2","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1073\/pnas.0630530100","volume":"100","author":"DD Richman","year":"2003","unstructured":"Richman, D. D., Wrin, T., Little, S. J. & Petropoulos, C. J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl Acad. Sci. USA 100, 4144\u20134149 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2347_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nature01470","volume":"422","author":"X Wei","year":"2003","unstructured":"Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307\u2013312 (2003).","journal-title":"Nature"},{"key":"2347_CR4","doi-asserted-by":"publisher","first-page":"18514","DOI":"10.1073\/pnas.0504658102","volume":"102","author":"SD Frost","year":"2005","unstructured":"Frost, S. D. et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl Acad. Sci. USA 102, 18514\u201318519 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2347_CR5","doi-asserted-by":"publisher","first-page":"6155","DOI":"10.1128\/JVI.00093-06","volume":"80","author":"SG Deeks","year":"2006","unstructured":"Deeks, S. G. et al. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J. Virol. 80, 6155\u20136164 (2006).","journal-title":"J. Virol."},{"key":"2347_CR6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1128\/JVI.02036-08","volume":"83","author":"DN Sather","year":"2009","unstructured":"Sather, D. N. et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83, 757\u2013769 (2009).","journal-title":"J. Virol."},{"key":"2347_CR7","doi-asserted-by":"publisher","first-page":"e1001251","DOI":"10.1371\/journal.ppat.1001251","volume":"7","author":"I Mikell","year":"2011","unstructured":"Mikell, I. et al. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7, e1001251 (2011).","journal-title":"PLoS Pathog."},{"key":"2347_CR8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487\u2013491 (2015).","journal-title":"Nature"},{"key":"2347_CR9","doi-asserted-by":"publisher","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","volume":"7","author":"RM Lynch","year":"2015","unstructured":"Lynch, R. M. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319ra206 (2015).","journal-title":"Sci. Transl. Med."},{"key":"2347_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","volume":"23","author":"M Caskey","year":"2017","unstructured":"Caskey, M. et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23, 185\u2013191 (2017).","journal-title":"Nat. Med."},{"key":"2347_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/00002030-200201250-00012","volume":"16","author":"C Armbruster","year":"2002","unstructured":"Armbruster, C. et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 16, 227\u2013233 (2002).","journal-title":"AIDS"},{"key":"2347_CR12","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1097\/00002030-200210180-00006","volume":"16","author":"G Stiegler","year":"2002","unstructured":"Stiegler, G. et al. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS 16, 2019\u20132025 (2002).","journal-title":"AIDS"},{"key":"2347_CR13","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nm1244","volume":"11","author":"A Trkola","year":"2005","unstructured":"Trkola, A. et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11, 615\u2013622 (2005).","journal-title":"Nat. Med."},{"key":"2347_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","volume":"606","author":"MC Sneller","year":"2022","unstructured":"Sneller, M. C. et al. Combination anti-HIV antibodies provide sustained virological suppression. Nature 606, 375\u2013381 (2022).","journal-title":"Nature"},{"key":"2347_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","volume":"606","author":"C Gaebler","year":"2022","unstructured":"Gaebler, C. et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature 606, 368\u2013374 (2022).","journal-title":"Nature"},{"key":"2347_CR16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479\u2013484 (2018).","journal-title":"Nature"},{"key":"2347_CR17","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1038\/s41591-022-02023-7","volume":"28","author":"JD Gunst","year":"2022","unstructured":"Gunst, J. D. et al. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b\/2a, randomized trial. Nat. Med. 28, 2424\u20132435 (2022).","journal-title":"Nat. Med."},{"key":"2347_CR18","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/s41591-023-02547-6","volume":"29","author":"JD Gunst","year":"2023","unstructured":"Gunst, J. D. et al. Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial. Nat. Med. 29, 2547\u20132558 (2023).","journal-title":"Nat. Med."},{"key":"2347_CR19","doi-asserted-by":"publisher","first-page":"ofy242","DOI":"10.1093\/ofid\/ofy242","volume":"5","author":"SA Riddler","year":"2018","unstructured":"Riddler, S. A. et al. Randomized clinical trial to assess the impact of the broadly neutralizing HIV-1 monoclonal antibody VRC01 on HIV-1 persistence in individuals on effective ART. Open Forum Infect. Dis. 5, ofy242 (2018).","journal-title":"Open Forum Infect. Dis."},{"key":"2347_CR20","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","volume":"28","author":"B Julg","year":"2022","unstructured":"Julg, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat. Med. 28, 1288\u20131296 (2022).","journal-title":"Nat. Med."},{"key":"2347_CR21","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","volume":"24","author":"Y Bar-On","year":"2018","unstructured":"Bar-On, Y. et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat. Med. 24, 1701\u20131707 (2018).","journal-title":"Nat. Med."},{"key":"2347_CR22","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","volume":"27","author":"KE Stephenson","year":"2021","unstructured":"Stephenson, K. E. et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat. Med. 27, 1718\u20131724 (2021).","journal-title":"Nat. Med."},{"key":"2347_CR23","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/S2352-3018(23)00293-X","volume":"11","author":"JJ Eron","year":"2024","unstructured":"Eron, J. J. et al. Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study. Lancet HIV 11, e146\u2013e155 (2024).","journal-title":"Lancet HIV"},{"key":"2347_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06151-w","volume":"23","author":"MJ Lee","year":"2022","unstructured":"Lee, M. J. et al. The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial. Trials 23, 263 (2022).","journal-title":"Trials"},{"key":"2347_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50635-w","volume":"9","author":"R Rawi","year":"2019","unstructured":"Rawi, R. et al. Accurate prediction for antibody resistance of clinical HIV-1 isolates. Sci. Rep. 9, 14696 (2019).","journal-title":"Sci. Rep."},{"key":"2347_CR26","doi-asserted-by":"publisher","first-page":"10598","DOI":"10.1073\/pnas.1309215110","volume":"110","author":"AP West","year":"2013","unstructured":"West, A. P. et al. Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proc. Natl Acad. Sci. USA 110, 10598\u201310603 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2347_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.chom.2018.12.001","volume":"25","author":"CA Bricault","year":"2019","unstructured":"Bricault, C. A. et al. HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design. Cell Host Microbe 25, 59\u201372 (2019).","journal-title":"Cell Host Microbe"},{"key":"2347_CR28","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1128\/JVI.03608-14","volume":"89","author":"RM Lynch","year":"2015","unstructured":"Lynch, R. M. et al. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J. Virol. 89, 4201\u20134213 (2015).","journal-title":"J. Virol."},{"key":"2347_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2020.01.010","volume":"180","author":"P Schommers","year":"2020","unstructured":"Schommers, P. et al. Restriction of HIV-1 escape by a highly broad and potent neutralizing antibody. Cell 180, 471\u2013489 (2020).","journal-title":"Cell"},{"key":"2347_CR30","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.immuni.2018.12.017","volume":"50","author":"AS Dingens","year":"2019","unstructured":"Dingens, A. S., Arenz, D., Weight, H., Overbaugh, J. & Bloom, J. D. An antigenic atlas of HIV-1 escape from broadly neutralizing antibodies distinguishes functional and structural epitopes. Immunity 50, 520\u2013532 (2019).","journal-title":"Immunity"},{"key":"2347_CR31","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.chom.2023.05.025","volume":"31","author":"CE Radford","year":"2023","unstructured":"Radford, C. E. et al. Mapping the neutralizing specificity of human anti-HIV serum by deep mutational scanning. Cell Host Microbe 31, 1200\u20131215 (2023).","journal-title":"Cell Host Microbe"},{"key":"2347_CR32","doi-asserted-by":"publisher","first-page":"e0019525","DOI":"10.1128\/jvi.00195-25","volume":"99","author":"CE Radford","year":"2025","unstructured":"Radford, C. E. & Bloom, J. D. Comprehensive maps of escape mutations from antibodies 10-1074 and 3BNC117 for Envs from two divergent HIV strains. J. Virol. 99, e0019525 (2025).","journal-title":"J. Virol."},{"key":"2347_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/COH.0000000000000802","volume":"18","author":"GS Frattari","year":"2023","unstructured":"Frattari, G. S., Caskey, M. & Sogaard, O. S. Broadly neutralizing antibodies for HIV treatment and cure approaches. Curr. Opin. HIV AIDS 18, 157\u2013163 (2023).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"2347_CR34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.chom.2012.08.012","volume":"12","author":"SJ Wilson","year":"2012","unstructured":"Wilson, S. J. et al. Inhibition of HIV-1 particle assembly by 2\u2032,3\u2032-cyclic-nucleotide 3\u2032-phosphodiesterase. Cell Host Microbe 12, 585\u2013597 (2012).","journal-title":"Cell Host Microbe"},{"key":"2347_CR35","doi-asserted-by":"publisher","first-page":"7738","DOI":"10.1128\/JVI.00214-14","volume":"88","author":"I Busnadiego","year":"2014","unstructured":"Busnadiego, I. et al. Host and viral determinants of Mx2 antiretroviral activity. J. Virol. 88, 7738\u20137752 (2014).","journal-title":"J. Virol."},{"key":"2347_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pbio.3001010","volume":"18","author":"E Bons","year":"2020","unstructured":"Bons, E., Leemann, C., Metzner, K. J. & Regoes, R. R. Long-term experimental evolution of HIV-1 reveals effects of environment and mutational history. PLoS Biol. 18, 1\u201318 (2020).","journal-title":"PLoS Biol."},{"key":"2347_CR37","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1126\/science.7824947","volume":"267","author":"JM Coffin","year":"1995","unstructured":"Coffin, J. M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267, 483\u2013489 (1995).","journal-title":"Science"},{"key":"2347_CR38","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1126\/science.aaf0972","volume":"352","author":"T Schoofs","year":"2016","unstructured":"Schoofs, T. et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352, 997\u20131001 (2016).","journal-title":"Science"},{"key":"2347_CR39","doi-asserted-by":"publisher","first-page":"9040","DOI":"10.1073\/pnas.1820333116","volume":"116","author":"R Van Duyne","year":"2019","unstructured":"Van Duyne, R., Kuo, L. S., Pham, P., Fujii, K. & Freed, E. O. Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle. Proc. Natl Acad. Sci. USA 116, 9040\u20139049 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2347_CR40","doi-asserted-by":"publisher","unstructured":"Hikichi, Y. et al. Mechanistic analysis of the broad antiretroviral resistance conferred by HIV-1 envelope glycoprotein mutations. mBio https:\/\/doi.org\/10.1128\/mBio.03134-20 (2021).","DOI":"10.1128\/mBio.03134-20"},{"key":"2347_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn0042","volume":"10","author":"Y Hikichi","year":"2024","unstructured":"Hikichi, Y., Grover, J. R., Sch\u00e4fer, A., Mothes, W. & Freed, E. O. Epistatic pathways can drive HIV-1 escape from integrase strand transfer inhibitors. Sci. Adv. 10, eadn0042 (2024).","journal-title":"Sci. Adv."},{"key":"2347_CR42","doi-asserted-by":"publisher","unstructured":"Mouquet, H. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl Acad. Sci. USA https:\/\/doi.org\/10.1073\/pnas.1217207109 (2012).","DOI":"10.1073\/pnas.1217207109"},{"key":"2347_CR43","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41594-019-0344-5","volume":"26","author":"Z Yang","year":"2019","unstructured":"Yang, Z., Wang, H., Liu, A. Z., Gristick, H. B. & Bjorkman, P. J. Asymmetric opening of HIV-1 Env bound to CD4 and a coreceptor-mimicking antibody. Nat. Struct. Mol. Biol. 26, 1167\u20131175 (2019).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2347_CR44","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.immuni.2017.03.017","volume":"46","author":"JH Lee","year":"2017","unstructured":"Lee, J. H. et al. A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic \u03b2-hairpin structure. Immunity 46, 690\u2013702 (2017).","journal-title":"Immunity"},{"key":"2347_CR45","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.tim.2020.03.007","volume":"28","author":"Q Wang","year":"2020","unstructured":"Wang, Q., Finzi, A. & Sodroski, J. The conformational states of the HIV-1 envelope glycoproteins. Trends Microbiol. 28, 655\u2013667 (2020).","journal-title":"Trends Microbiol."},{"key":"2347_CR46","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","volume":"155","author":"YC Ho","year":"2013","unstructured":"Ho, Y. C. et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540\u2013551 (2013).","journal-title":"Cell"},{"key":"2347_CR47","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.it.2007.08.009","volume":"28","author":"VV Ganusov","year":"2007","unstructured":"Ganusov, V. V. & De Boer, R. J. Do most lymphocytes in humans really reside in the gut?. Trends Immunol. 28, 514\u2013518 (2007).","journal-title":"Trends Immunol."},{"key":"2347_CR48","doi-asserted-by":"publisher","first-page":"43170","DOI":"10.1074\/jbc.M112.399402","volume":"287","author":"D Guo","year":"2012","unstructured":"Guo, D. et al. A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01. J. Biol. Chem. 287, 43170\u201343179 (2012).","journal-title":"J. Biol. Chem."},{"key":"2347_CR49","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01730-24","volume":"99","author":"P Cohen","year":"2025","unstructured":"Cohen, P. et al. Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703\/HPTN081 trial: implications for cross-resistance. J. Virol. 99, e0173024 (2025).","journal-title":"J. Virol."},{"key":"2347_CR50","doi-asserted-by":"publisher","first-page":"12676","DOI":"10.1128\/JVI.01893-12","volume":"86","author":"DN Sather","year":"2012","unstructured":"Sather, D. N. et al. Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus. J. Virol. 86, 12676\u201312685 (2012).","journal-title":"J. Virol."},{"key":"2347_CR51","doi-asserted-by":"publisher","first-page":"e1007238","DOI":"10.1371\/journal.ppat.1007238","volume":"14","author":"Y Otsuka","year":"2018","unstructured":"Otsuka, Y. et al. Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies. PLoS Pathog. 14, e1007238 (2018).","journal-title":"PLoS Pathog."},{"key":"2347_CR52","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.chom.2017.05.003","volume":"21","author":"AS Dingens","year":"2017","unstructured":"Dingens, A. S., Haddox, H. K., Overbaugh, J. & Bloom, J. D. Comprehensive mapping of HIV-1 escape from a broadly neutralizing antibody. Cell Host Microbe 21, 777\u2013787 (2017).","journal-title":"Cell Host Microbe"},{"key":"2347_CR53","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/s41590-025-02286-5","volume":"26","author":"L Gieselmann","year":"2025","unstructured":"Gieselmann, L. et al. Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy. Nat. Immunol. 26, 2016\u20132029 (2025).","journal-title":"Nat. Immunol."},{"key":"2347_CR54","doi-asserted-by":"publisher","first-page":"8925","DOI":"10.1128\/JVI.00758-09","volume":"83","author":"ES Gray","year":"2009","unstructured":"Gray, E. S. et al. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J. Virol. 83, 8925\u20138937 (2009).","journal-title":"J. Virol."},{"key":"2347_CR55","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.virol.2017.12.002","volume":"515","author":"J Pr\u00e9vost","year":"2018","unstructured":"Pr\u00e9vost, J. et al. Envelope glycoproteins sampling states 2\/3 are susceptible to ADCC by sera from HIV-1-infected individuals. Virology 515, 38\u201345 (2018).","journal-title":"Virology"},{"key":"2347_CR56","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.chom.2016.08.005","volume":"20","author":"M Kane","year":"2016","unstructured":"Kane, M. et al. Identification of interferon-stimulated genes with antiretroviral activity. Cell Host Microbe 20, 392\u2013405 (2016).","journal-title":"Cell Host Microbe"},{"key":"2347_CR57","unstructured":"Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at https:\/\/arxiv.org\/abs\/1303.3997 (2013)."},{"key":"2347_CR58","doi-asserted-by":"publisher","first-page":"11189","DOI":"10.1093\/nar\/gks918","volume":"40","author":"A Wilm","year":"2012","unstructured":"Wilm, A. et al. LoFreq: A sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 40, 11189\u201311201 (2012).","journal-title":"Nucleic Acids Res."},{"key":"2347_CR59","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/bioinformatics\/btu587","volume":"31","author":"BM Verbist","year":"2015","unstructured":"Verbist, B. M. et al. VirVarSeq: a low-frequency virus variant detection pipeline for Illumina sequencing using adaptive base-calling accuracy filtering. Bioinformatics 31, 94\u2013101 (2015).","journal-title":"Bioinformatics"},{"key":"2347_CR60","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","unstructured":"Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409, 131\u2013146 (2014).","journal-title":"J. Immunol. Methods"},{"key":"2347_CR61","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1101\/gr.849004","volume":"14","author":"GE Crooks","year":"2004","unstructured":"Crooks, G. E., Hon, G., Chandonia, J. M. & Brenner, S. E. WebLogo: a sequence logo generator. Genome Res. 14, 1188\u20131190 (2004).","journal-title":"Genome Res."},{"key":"2347_CR62","doi-asserted-by":"publisher","first-page":"6097","DOI":"10.1093\/nar\/18.20.6097","volume":"18","author":"TD Schneider","year":"1990","unstructured":"Schneider, T. D. & Stephens, R. M. Sequence logos: a new way to display consensus sequences. Nucleic Acids Res. 18, 6097\u20136100 (1990).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02347-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02347-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02347-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:03:48Z","timestamp":1780585428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02347-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":62,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["2347"],"URL":"https:\/\/doi.org\/10.1038\/s41564-026-02347-x","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The following authors declare competing interests: M.C.N. is listed as an inventor on patents for the antibodies 3BNC117 and 10-1074 and M.C. participates in advisory boards for Gilead, Merck and ViiV. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}